Biomea Fusion Inc. Common Stock (BMEA)
Stock · NASDAQ · Health Care
$0.869as of 10/16/2026
Price chart
Active signals
BMEA Signal Track Record
How signals performed across all stocks →What BMEA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | +0.8% | 51% | September 23, 2026 |
| Bollinger Band Breakout | 28 | -6.7% | 43% | September 2, 2026 |
| Bollinger Band Breakdown | 20 | -0.6% | 50% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -11.0% | 22% | October 9, 2026 |
| Any 20-session window (baseline) | -2.1% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BMEA
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of i…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 37
- Website
- www.biomeafusion.com/
Fundamentals
- 1-day range
- $0.7995$0.9699
- Market cap
- $90.37M
- P/E (trailing)
- —
- P/E (forward)
- -0.92
- EPS (trailing)
- $-0.50
- Dividend yield
- —
- Beta
- -0.25
- Avg. volume
- 1.93M
Forecasts
6 analyst ratings
Biomea Fusion Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BMEABiomea Fusion Inc. Common Stock$0.869▲ 3.95%Market cap $90.37MP/E —$0.800501$2.24
- NTHINeOnc Technologies Holdings Inc. Common Stock$2.7▼ 1.82%Market cap $90.77MP/E —$2.5$12
- FBIOFortress Biotech Inc. Common Stock$1.87▼ 2.09%Market cap $92.02MP/E 0.58$1.88$4.53
- VRCAVerrica Pharmaceuticals Inc. Common Stock$3.6▼ 4.89%Market cap $92.08MP/E —$3.28$9.82
- GOSSGossamer Bio Inc. Common Stock$8.77▼ 1.35%Market cap $87.21MP/E —$8.77$309.6
- MAIAMAIA Biotechnology Inc. Common Stock$1.1▼ 1.79%Market cap $86.34MP/E —$0.87$3.19
- HRTXHeron Therapeutics Inc. Common Stock$0.36▼ 5.26%Market cap $94.45MP/E —$0.261$1.58
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BMEA Biomea Fusion Inc. Common Stock | $90.37M | — | $0.869 | ▲ 3.95% | $0.800501$2.24 |
| NTHI NeOnc Technologies Holdings Inc. Common Stock | $90.77M | — | $2.7 | ▼ 1.82% | $2.5$12 |
| FBIO Fortress Biotech Inc. Common Stock | $92.02M | 0.58 | $1.87 | ▼ 2.09% | $1.88$4.53 |
| VRCA Verrica Pharmaceuticals Inc. Common Stock | $92.08M | — | $3.6 | ▼ 4.89% | $3.28$9.82 |
| GOSS Gossamer Bio Inc. Common Stock | $87.21M | — | $8.77 | ▼ 1.35% | $8.77$309.6 |
| MAIA MAIA Biotechnology Inc. Common Stock | $86.34M | — | $1.1 | ▼ 1.79% | $0.87$3.19 |
| HRTX Heron Therapeutics Inc. Common Stock | $94.45M | — | $0.36 | ▼ 5.26% | $0.261$1.58 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Citizens Reiterates Market Outperform on Biomea Fusion, Maintains $7 Price Targetbenzinga · 10/14/2026
- Brookline Capital Initiates Coverage On Biomea Fusion with Buy Rating, Announces Price Target of $10Benzinga · 10/7/2026
- Biomea Pulls Equity Raise, Trading Dilution Relief For Near-Term Runway PressureSeekingAlpha · 9/24/2026
- Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study DataBenzinga · 9/23/2026
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga · 9/23/2026
- Biomea Fusion Announces Termination of Proposed Public Offering of SecuritiesYahoo · 9/23/2026
- Biomea Fusion Terminates Proposed Public Offering Of Securities Due To Market ConditionsBenzinga · 9/23/2026
- Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving PremarketBenzinga · 9/23/2026
- Biomea Fusion Shares Fall 19% After Hours: Here’s WhyBenzinga · 9/23/2026
Insider Activity
Insider Actions →- Averill Julianne · June 10, 2026 · Grant173.7K
- Ray Sumita · June 10, 2026 · Grant196.3K
- Faust Elizabeth · June 10, 2026 · Grant196.3K
- Eric Aguiar · June 10, 2026 · Grant196.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 24.53M
- Total value held
- $37.37M
- Institutional holders
- 61
- Unknown8.81M
- Unknown2.60M
- Unknown2.05M
- Unknown1.31M
- Unknown1.20M
- Unknown903.7K
- Unknown856.7K
- Unknown654.6K
- Unknown641.4K
- Unknown557.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Biomea Fusion Cancels Equity Offering, Shares Drop 19%
Biomea Fusion announced the termination of its proposed public equity offering, citing market conditions. The cancellation removes expected dilution relief and leaves the company with near‑term runway pressure. Following the news, the stock fell about 19% in after‑hours trading. The development occurs amid broader health‑care stock activity.
Biomea Fusion Cancels Equity Offering, Shares Drop 19%. Biomea Fusion announced the termination of its proposed public equity offering, citing market conditions. The cancellation removes expected dilution relief and leaves the company with near‑term runway pressure. Following the news, the stock fell about 19% in after‑hours trading. The development occurs amid broader health‑care stock activity.